RXi also broke out its financial results for 2010 in the filing, reporting a drop in its net loss amid lower research and development spending. The company said, however, that it anticipates its expenses to increase going forward on NeuVax-related expenses.

RXi bought the firm for around $7.2 million in order to accelerate its move from a research-based company to a clinical-stage one.

RXi's pending acquisition of Apthera will also enable the company to explore the combination of its RNAi technologies with Apthera's peptide know-how, RXi's CEO said.

The deal gives RXi a late-stage peptide immunotherapy for breast cancer and marks a shift in strategy that nudges the company from its previous focus as a pure-play RNAi shop.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.